crinecerfont

Crinecerfont (brand name CRENESSITY) is an oral, selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist developed by Neurocrine Biosciences. It is indicated as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. By antagonizing CRF1 receptors in the pituitary gland, crinecerfont reduces the secretion of adrenocorticotropic hormone (ACTH), which in turn decreases the production of adrenal androgens through a glucocorticoid-independent mechanism. This allows for improved androgen control and potentially reduces the need for supraphysiologic doses of glucocorticoids, which are associated with significant long-term side effects. The drug was approved by the U.S. Food and Drug Administration in December 2024.

Brand names

CRENESSITY

Other names

crinecerfont